Conditional Expression of Human PPARδ and a Dominant Negative Variant of hPPARδ In Vivo

Table 1

Effect of GW501516 treatment on body weight (g) and hepatic triglycerides (mg/g of liver) in nontransgenic, hPPARδ and hPPARδΔAF2 mice.

Genotype	Treatment	Number of mice	Starting weight (g)^a	Ultimate weight (g)^a	𝑃 value^b	Hepatic trigs (mg/g)	𝑃 value
Non-Tg	Control	5	24.35±0.44	24.03±0.53	0.1592	9.68±1.18
hPPARδ	Control	5	22.27±0.98	22.15±1.27	0.972	15.73±3.62	ns 0.152^c
hPARδΔAF2	Control	5	22.02±1.03	21.96±1.18	0.8675	52.98±6.06	***0.0001^c
Non-Tg	GW	5	21.36±0.44	20.77±0.53	0.1962	22.66±2.31	**0.0011^d
hPPARδ	GW	5	21.78±0.98	18.4±1.27	*0.0179	47.53±6.24	**0.0024^d
hPARδΔAF2	GW	5	21.97±1.03	22.14±1.18	0.5767	25.66±2.16	**0.0023^d

Values are the means ± S.E.M.
^aValues adjusted for sex.
^b𝑃 value of weight difference (ultimate body weight minus initial body weight; paired t-test).
^c𝑃 value of difference between level of hepatic triglycerides: non-Tg control versus transgenics control (unpaired t-test).
^d𝑃 value of difference between level of hepatic triglycerides: control versus treated groups (unpaired t-test).